Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety, tolerability, PK and PD of the CB1 antagonist ANEB-001 in an acute cannabinoid intoxication challenge.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cannabinoid Intoxication

Drugs mentioned

• ANEB-001 (ANEB-001)

Snippet

Sponsor: Anebulo Pharmaceuticals | Conditions: Acute Cannabinoid Intoxication | Phase 2 | Status: COMPLETED